Scholarlink

<p>In this paper, an oral liquid containing <i>Magnolia officinalis</i> polysaccharide was formulated and its hypoglycemic effects were investigated. An orthogonal test was conducted based on single-factor experiments to optimize the formulation guided by sensory evaluations. Its stability and safety were also assessed. The oral liquid was administered via gavage to STZ-induced diabetic mice at low (2.5&#xa0;mL/kg), medium (5&#xa0;mL/kg) and high (10&#xa0;mL/kg) doses. Blood glucose levels were monitored weekly. After 8&#xa0;weeks of treatment, the oral glucose tolerance test (OGTT) was performed and fasting insulin levels, lipid profiles, oxidative stress levels in serum and liver, and the activities of hexokinase (HK) and pyruvate kinase (PK) in the liver were measured. Results indicated that the optimal formulation contained 0.2% steviol glycosides, 0.2% ascorbic acid, a pH of 5.0, and 0.5% ginger juice, yielding a sensory evaluation score of 94 ± 0.58. The oral liquid remained stable at room temperature for 12&#xa0;months and passed acute oral toxicity testing. After 8&#xa0;weeks, diabetic mice exhibited a significant reduction in blood glucose levels (<i>P</i> &lt; 0.01), enhanced glucose metabolism, increased fasting insulin levels, and decreased lipid levels. Additionally, antioxidant capacity improved, and HK and PK activities increased significantly in the diabetic mice. In conclusion, the <i>Magnolia officinalis</i> polysaccharide oral liquid demonstrated potential antidiabetic effects by promoting glucose utilization in peripheral tissues, increasing fasting insulin levels, and enhancing antioxidant capacity alongside HK and PK activities. This formulation could represent a promising hypoglycemic health product.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preparation and Hypoglycemic Effect of Magnolia Officinalis Polysaccharide Oral Liquid

  • 期刊论文

  • 发表日期：

    2025年1月8日

查看全文
  • Jinkun Liu,
  • Wenle Liu,
  • Yuyan Zhang,
  • Qindan Tian,
  • Minshu Xia,
  • Qiuyue Zhao,
  • Dewei Zhang,
  • Jingjing He,
  • Daocai Wang,
  • Xiqiang Zhu,
  • Xiaopeng Liu,
  • Ning Jiang

摘要

In this paper, an oral liquid containing Magnolia officinalis polysaccharide was formulated and its hypoglycemic effects were investigated. An orthogonal test was conducted based on single-factor experiments to optimize the formulation guided by sensory evaluations. Its stability and safety were also assessed. The oral liquid was administered via gavage to STZ-induced diabetic mice at low (2.5 mL/kg), medium (5 mL/kg) and high (10 mL/kg) doses. Blood glucose levels were monitored weekly. After 8 weeks of treatment, the oral glucose tolerance test (OGTT) was performed and fasting insulin levels, lipid profiles, oxidative stress levels in serum and liver, and the activities of hexokinase (HK) and pyruvate kinase (PK) in the liver were measured. Results indicated that the optimal formulation contained 0.2% steviol glycosides, 0.2% ascorbic acid, a pH of 5.0, and 0.5% ginger juice, yielding a sensory evaluation score of 94 ± 0.58. The oral liquid remained stable at room temperature for 12 months and passed acute oral toxicity testing. After 8 weeks, diabetic mice exhibited a significant reduction in blood glucose levels (P < 0.01), enhanced glucose metabolism, increased fasting insulin levels, and decreased lipid levels. Additionally, antioxidant capacity improved, and HK and PK activities increased significantly in the diabetic mice. In conclusion, the Magnolia officinalis polysaccharide oral liquid demonstrated potential antidiabetic effects by promoting glucose utilization in peripheral tissues, increasing fasting insulin levels, and enhancing antioxidant capacity alongside HK and PK activities. This formulation could represent a promising hypoglycemic health product.